Unlocking Biopharma Efficiency: How Perfusion Technology Maximizes Productivity and Scalability

Perfusion-based upstream processing is transforming biopharmaceutical manufacturing. Perfusion allows continuous media exchange and enables manufacturers to achieve higher cell densities and viabilities, improving overall product quality. Join the webinar to learn about Samsung Biologics’ N-1 perfusion technology, process control considerations, and more.

Register Free: https://www.biopharminternational.com/bp_w/perfusion_technology

Event Overview:

Perfusion-based upstream processing is transforming the production landscape for biopharmaceuticals. Unlike a traditional fed-batch system, perfusion enables continuous media exchange, sustaining high cell density and improving viability over extended durations. This leads to significantly higher productivity, enhancing process competitiveness and expanding patient access to affordable drugs.

As the biopharma market demands lower costs and faster turnarounds, perfusion technology provides a scalable and cost-efficient solution. This webinar explores implementation strategies, process control considerations, and perfusion-based case studies.

Key Learning Objectives:

• Identify limits of traditional fed-batch cell culture
• Explore benefits of perfusion processes
• Determine factors for successful scale up

Who Should Attend:

• Process development scientists and engineers who are involved in upstream processes
• Manufacturing and operation managers focused on enhancing efficiency and throughput
• Field application scientists and those in technical support roles engaged in product evaluation and implementation
• Scientists evaluating new technologies

Speaker:

Seohyeon Song
Lead Scientist of Upstream Process
Samsung Biologics

Seohyeon Song received his master’s degree in target protein discovery and cell line development from the Pohang University of Science and Technology in 2014. He has over 8 years of experience in technology transfer, process analysis, and process validation in a CGMP environment. He also has strong expertise in upstream operations for monoclonal antibody products. Prior to joining Samsung Biologics, Seohyeon worked at CJ BIO Research Institute to support strain development, fermentation process optimization, production technology development, and novel biomaterial development.

Register Free: https://www.biopharminternational.com/bp_w/perfusion_technology